Immunocore HoldingsIMCR -0.31%78 Days Payable is 5,731.61 as of Mar. 2026, which is 64% above its 10-year median of 3,492.20. GuruFocus rates IMCR with a GF Score™ of 78/100 and a GF Value™ of $46.12 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 704 Biotechnology companies, Immunocore Holdings ranks better than 90.34% on this metric.
The historical rank and industry rank for Immunocore Holdings's Days Payable or its related term are showing as below:
IMCR'
s Days Payable Range Over the Past 10 Years
Min: 1774.56 Med: 3492.2 Max: 5675.27
Current: 2030.27
During the past 8 years, Immunocore Holdings's highest Days Payable was 5675.27. The lowest was 1774.56. And the median was 3492.20.
IMCR's Days Payable is ranked better than 90.34% of 704
companies
in the Biotechnology industry
Industry Median: 113.56
vs IMCR: 2030.27
Immunocore Holdings's Days Payable
increased
from Mar. 2025 (2,976.06) to Mar. 2026 (5,731.61).
It may suggest that Immunocore Holdingsdelayed paying its suppliers.
Immunocore Holdings Days Payable Related Terms
Immunocore Holdings Days Payable Historical Data
* Premium members only.
The historical data trend for Immunocore Holdings's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Immunocore Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunocore Holdings Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immunocore Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where Immunocore Holdings's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Immunocore Holdings's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunocore Holdings (IMCR) has a Days Payable of 5,731.61 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Immunocore Holdings and its competitors. This is 64% above median its historical median of 3,492.20. Over the past decade, Immunocore Holdings' Days Payable has ranged from 1,774.56 to 5,675.27. According to the industry distribution chart, Immunocore Holdings ranks #68 out of 704 companies in the Biotechnology industry, placing it in the top 9.7%.
Is Immunocore Holdings' Days Payable too high?
Immunocore Holdings' current Days Payable of 5,731.61 is 64% above median its 10-year median of 3,492.20. Over the past 10 years, this metric has ranged from a low of 1,774.56 to a high of 5,675.27. The Biotechnology industry median Days Payable is 113.56. Immunocore Holdings' value of 5,731.61 is 4947.2% above this industry median. Based on the distribution chart, Immunocore Holdings ranks #68 out of 704 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Immunocore Holdings has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Immunocore Holdings' Days Payable compare to MAZE and DMRA?
According to the Biotechnology industry distribution chart, Immunocore Holdings ranks #68 out of 704 companies for Days Payable. This places Immunocore Holdings in the top 10% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.56. Immunocore Holdings' value of 5,731.61 is 4947.2% above this benchmark. Historically, Immunocore Holdings' own Days Payable has ranged from 1,774.56 to 5,675.27 over the past decade. While the company's 10-year median is 3,492.20 vs. the industry median of 113.56, Immunocore Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immunocore Holdings's current Days Payable of 5,731.61 is 4947.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Immunocore Holdings and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunocore Holdings's current Days Payable is 5,731.61, which is 64% above median its own 10-year median of 3,492.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunocore Holdings stock overvalued right now?
Based on GuruFocus' analysis, Immunocore Holdings (IMCR) is currently considered Possible Value Trap. The stock's GF Value™ is $46.12, compared to a current price of $31.65 — trading 31.4% below its estimated fair value. The current Days Payable is 5,731.61, which is 64% above median its 10-year median of 3,492.20 and 4947.2% above the Biotechnology industry median of 113.56. Immunocore Holdings' overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Immunocore Holdings (IMCR), the current Days Payable is 5,731.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immunocore Holdings (IMCR) Overvalued in 2026?
Based on GuruFocus' analysis, Immunocore Holdings stock appears to be undervalued.
The current stock price of $31.65 is trading 31.4% below its estimated GF Value™ of $46.12.
GuruFocus considers Immunocore Holdings to be Possible Value Trap.
Key valuation signals for IMCR:
Days Payable: 5,731.61 (64% above median its 10-year median of 3,492.20)
GF Value™: $46.12 vs. price of $31.65 (31.4% below fair value)
Industry Position: 4947.2% above the Biotechnology median (#68 of 704)
No single metric tells the full story. See the IMCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
78GF Score
Get the complete analysis for IMCR
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMCR has been successfully added to your 
